Nathan John Robison, MD

Associate Professor of Clinical Pediatrics

Image of Nathan John Robison, MD
Is this your profile? Click to edit

Overview

After completing his residency and fellowship at Children’s Hospital Los Angeles, Dr. Robison completed an additional fellowship in Pediatric Neuro-Oncology at the Dana-Farber / Children’s Hospital Cancer Center in Boston. He served as clinical instructor at Harvard Medical School and attending staff in the Pediatric Neuro-Oncology Program at Dana Farber Cancer Institute and Boston Children’s Hospital from 2010 to 2013.

In April 2013 he joined the faculty of the University of Southern California Keck School of Medicine as assistant professor of pediatrics, and now serves as attending staff in the Pediatric Neuro-Oncology Program at Children’s Hospital Los Angeles.

Dr. Robison’s primary research focus is developing clinical trials that test new strategies in the treatment of children with brain tumors. Specific areas of interest include molecular targeted treatment of low-grade glioma, diffuse pontine glioma, and medulloblastoma; novel treatments targeting the tumor microenvironment, including antiangiogenic and immunomodulatory strategies; and neurofibromatosis.

Publications

  • An Exome Capture-Based RNA-Sequencing Assay for Genome-Wide Identification and Prioritization of Clinically Important Fusions in Pediatric Tumors J Mol Diagn. 2024 Feb; 26(2):127-139. . View in PubMed
  • Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group Neuro Oncol. 2024 03 04; 26(3):407-416. . View in PubMed
  • Addendum: Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Oncotarget. 2023 May 19; 14:502. . View in PubMed
  • Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047) Neuro Oncol. 2023 12 08; 25(12):2262-2272. . View in PubMed
  • Cardiac Function in Children and Young Adults Treated with MEK Inhibitors: A Retrospective Cohort Study Pediatr Cardiol. 2022 Aug; 43(6):1223-1228. . View in PubMed
  • MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus Neuro Oncol. 2022 11 02; 24(11):1845-1856. . View in PubMed
  • Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children Pediatr Blood Cancer. 2021 04; 68(4):e28833. . View in PubMed
  • Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients J Pediatr Hematol Oncol. 2021 11 01; 43(8):e1201-e1204. . View in PubMed
  • NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas J Clin Oncol. 2021 03 01; 39(7):797-806. . View in PubMed
  • Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab037. . View in PubMed
  • Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group Lancet Oncol. 2020 06; 21(6):e305-e316. . View in PubMed
  • Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report Neuro Oncol. 2020 11 26; 22(11):1696-1704. . View in PubMed
  • A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study Neuro Oncol. 2020 10 14; 22(10):1527-1535. . View in PubMed
  • Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens J Neurooncol. 2019 Nov; 145(2):375-383. . View in PubMed
  • Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Oncotarget. 2019 Jan 11; 10(4):551-557. . View in PubMed
  • Clinical and neuropsychological outcome of pediatric non-midline central nervous system germinoma treated with chemotherapy and reduced dose/volume irradiation: The Children’s Hospital Los Angeles experience Pediatr Blood Cancer. 2019 12; 66(12):e27983. . View in PubMed
  • Unusual radiological and histological presentation of a diffuse leptomeningeal glioneuronal tumor (DLGNT) in a 13-year-old girl Childs Nerv Syst. 2019 09; 35(9):1609-1614. . View in PubMed
  • A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children’s Oncology Group J Neurooncol. 2018 Dec; 140(3):575-582. . View in PubMed
  • Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors J Neurooncol. 2018 May; 138(1):199-207. . View in PubMed
  • Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma Neuro Oncol. 2018 10 09; 20(11):1547-1555. . View in PubMed
  • Changing Trends in Brain Imaging Technique for Pediatric Patients with Ventriculoperitoneal Shunts Pediatr Neurosurg. 2018; 53(2):116-120. . View in PubMed
  • Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor J Neurosurg Pediatr. 2017 Jul; 20(1):51-55. . View in PubMed
  • Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma J Pediatr Hematol Oncol. 2017 11; 39(8):e473-e475. . View in PubMed
  • Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy Neuro Oncol. 2016 Jan; 18(1):126-31. . View in PubMed
  • Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children’s oncology group report Cancer. 2015 Dec 01; 121(23):4205-11. . View in PubMed
  • Tumor-associated macrophages in SHH subgroup of medulloblastomas Clin Cancer Res. 2015 Mar 15; 21(6):1457-65. . View in PubMed
  • Diffuse intrinsic pontine glioma: a reassessment J Neurooncol. 2014 Aug; 119(1):7-15. . View in PubMed
  • Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9. . View in PubMed
  • A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer Pediatr Blood Cancer. 2014 Apr; 61(4):636-42. . View in PubMed
  • PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas Clin Cancer Res. 2014 Feb 15; 20(4):827-36. . View in PubMed
  • Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells Clin Immunol. 2013 Oct; 149(1):55-64. . View in PubMed
  • Predictors of neoplastic disease in children with isolated pituitary stalk thickening Pediatr Blood Cancer. 2013 Oct; 60(10):1630-5. . View in PubMed
  • Morning glory disc anomaly in association with ipsilateral optic nerve glioma Arch Ophthalmol. 2012 Aug; 130(8):1082-3. . View in PubMed
  • Identification of novel biologic targets in the treatment of newly diagnosed diffuse intrinsic pontine glioma Am Soc Clin Oncol Educ Book. 2012; 625-8. . View in PubMed
  • Diffuse central neurocytoma with craniospinal dissemination J Clin Neurosci. 2012 Jan; 19(1):163-6. . View in PubMed
  • Cerebral sinus thrombosis in a child with active ulcerative colitis and factor V Leiden Pediatr Blood Cancer. 2009 Jul; 52(7):867-9. . View in PubMed
  • Causes of nursery death beyond the neonatal period J Perinatol. 2003 Mar; 23(2):142-7. . View in PubMed